Clinical trials: Classic Hodgkin Lymphoma
Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Classical Hodgkin Lymphoma
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
This study involved patients that have a cancer called diffuse large B cell lymphoma (DLBCL), NK and T cell lymphomas (NK/TL) or classical Hodgkin lymphoma (cHL) (hereafter these 3 diseases will be referred to as lymphoma).
- Trial name
- NCT04288726
- Testing
- CD30.CAR-EBVST cells
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Baylor College of Medicine
Hodgkin Disease, Lymphoma, Large-cell, Anaplastic
A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian Federation
The purpose of this study is to describe patterns of treatment used for cHL and sALCL in real world setting.
- Trial name
- KLIO (NCT03942263)
- Where
- 50 sites in Russia
- Volunteers
- 2,000 people
- Sponsor
- Takeda
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
This phase I trial studies the side effects and best dose of cellular immunotherapy following chemotherapy in treating patients with non-Hodgkin lymphomas, chronic lymphocytic leukemia, or B-cell prolymphocytic leukemia that has…
- Conditions
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia, High Grade B-Cell Lymphoma, Not Otherwise Specified, Post-Transplant Lymphoproliferative Disorder
- Trial name
- NCT02153580
- Testing
- Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Bendamustine Hydrochloride, Cyclophosphamide
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- City of Hope Medical Center
AIDS-Related Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma
This pilot phase I/II trial studies the side effects and the best dose of brentuximab vedotin when given together with combination chemotherapy and to see how well they work in treating patients with stage II-IV human…
- Conditions
- AIDS-Related Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma
- Trial name
- NCT01771107
- Testing
- Brentuximab Vedotin, Dacarbazine, Doxorubicin Hydrochloride
- Where
- 28 sites in United States, France
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Classic Hodgkin Lymphoma
A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma
The purpose of this study is to compare efficacy of IMM01 plus Tiselizumab with physician's choice chemotherapy of bendamustine or gemcitabine in participants with PD-(L)1-refractory classical Hodgkin Lymphoma.
- Trial name
- NCT06465446
- Testing
- Tislelizumab, IMM01, Bendamustine
- Volunteers
- 202 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Relapsed or Refractory Hodgkin Lymphoma
SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma
This is an open-label, phase I/II dose escalation and expansion trial. The primary objective of dose escalation phase I study is to evaluate the safety and feasibility of SHR1701 in patients with relapsed or refractory classical…
- Trial name
- NCT05896046
- Testing
- SHR2554+ SHR1701, SHR-1701
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
Recurrent Classical Hodgkin Lymphoma
JAK-inhibition in Recurrent Classical Hodgkin Lymphoma
The Purpose of this trial is: to determine the overall response rate (ORR, complete response [CR] + partial response [PR]) in patients with relapsed or refractory HL to determine the safety profile of ruxolitinib in patients with…
- Trial name
- JeRiCHO (NCT02164500)
- Testing
- Ruxolitinib
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- University of Cologne
Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma
Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas
This phase I/II trial studies the side effects and best dose of modified umbilical cord blood immune cells (natural killer [NK] cells) combined with the antibody AFM13 (AFM13-NK) and AFM13 alone in treating patients with CD30…
- Conditions
- Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Mycosis Fungoides
- Trial name
- NCT04074746
- Testing
- Anti-CD30/CD16A Monoclonal Antibody AFM13, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is to evaluate the clinical efficacy and safety of Camidanlumab Tesirine (ADCT-301) in participants with relapsed or refractory Hodgkin Lymphoma (HL).
- Trial name
- NCT04052997
- Testing
- Camidanlumab Tesirine
- Where
- 73 sites in United States, Belgium and 9 more
- Volunteers
- 117 people
- Sponsor
- ADC Therapeutics S.A.
Hodgkin Lymphoma
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
This is a phase II study using risk and response-adapted therapy for low, intermediate and high risk classical Hodgkin lymphoma. Chemotherapy regimens will be based on risk group assignment.
- Trial name
- NCT03755804
- Testing
- bendamustine, Etoposide, Doxorubicin
- Where
- 8 sites in United States
- Volunteers
- 232 people
- Sponsor
- St. Jude Children's Research Hospital
Hodgkin Disease
A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment
The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with…
- Trial name
- CheckMate 744 (NCT02927769)
- Testing
- Nivolumab, brentuximab vedotin, bendamustine
- Where
- 79 sites in United States, Canada and 9 more
- Volunteers
- 72 people
- Sponsor
- Bristol-Myers Squibb
Classical Hodgkin Lymphoma
Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents
The EuroNet-PHL-C2 trial is an international, multicentre, randomised controlled trial with the aims to reduce the indication for radiotherapy in newly diagnosed patients with classical Hodgkin lymphoma without compromising cure…
- Trial name
- NCT02684708
- Testing
- cyclophosphamide, vincristine, prednisone, dacarbazine, cyclo, vcr, pred, dacarb,etop and doxo
- Where
- 19 sites in Australia, Austria and 17 more
- Volunteers
- 2,921 people
- Sponsor
- University of Giessen
Non-small Cell Lung Cancer, Gastric Carcinoma
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are.
- Conditions
- Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma
- Trial name
- NCT04254107
- Testing
- SEA-TGT, sasanlimab, brentuximab vedotin
- Where
- 36 sites in United States, Canada and 4 more
- Volunteers
- 133 people
- Sponsor
- Seagen Inc.
Classical Hodgkin Lymphoma
Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma
By the implementation of the anti-PD-1 antibody pembrolizumab and given its possible synergy with RT, the aim of the present trial is to develop a chemotherapy-free first-line treatment for patients with newly diagnosed…
- Trial name
- PREFer (NCT06916416)
- Testing
- Pembrolizumab
- Volunteers
- 50 people
- Sponsor
- University of Cologne
Relapsed/Refractory Classical Hodgkin Lymphoma
Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma
< STUDY DESIGN > This study is a multi-center phase II trial in patients with relapsed or refractory Hodgkin's lymphoma after first-line treatment. < Treatment Schedule > 1.
- Trial name
- NCT05243693
- Testing
- Brentuximab vedotin
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- National Cancer Center, Korea
Lymphoma, Lymphoproliferative Disorder
KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment
RATIONALE: KX2-391 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of KX2-391 in treating patients with advanced…
- Conditions
- Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00646139
- Testing
- Src kinase inhibitor KX2-391, immunoenzyme technique, pharmacological study
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Roswell Park Cancer Institute
Classical Hodgkin Lymphoma
Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma
The aim of the trial is to improve first-line treatment for early unfavorable cHL by introduction of the anti-PD-1 antibody Nivolumab with a truncated standard chemotherapy (AVD).
- Trial name
- NIVAHL (NCT03004833)
- Testing
- Nivolumab, Adriamycin, Vinblastine
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- University of Cologne
Classical Hodgkin Lymphoma
Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma
This phase II trial studies the side effects of doxorubicin hydrochloride, pembrolizumab, vinblastine, and dacarbazine in treating patients with classical Hodgkin lymphoma.
- Trial name
- NCT03331341
- Testing
- Dacarbazine, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)
Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors
This is a prospective randomized open-label, multicenter, 2-arm study to assess the role of healthy LifeStyle implemented Survivorship Care Plan (LS-SCP) in modifying the Quality of Life (QoL) in a population of long-term…
- Conditions
- Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL)
- Trial name
- NCT05934084
- Testing
- Lifestyles Implemented-Survivorship Care Plan (LS-SCP)
- Where
- 40 sites in Italy
- Volunteers
- 552 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Hodgkin Lymphoma
Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study.
This is a retrospective, monocenter and non-interventional study. Data were retrospectively collected from all patients who completed the BV-Bs scheme in the time period between 1 September 2013 and 1 September 2023.
- Trial name
- HL_PR/R-B (NCT06295211)
- Testing
- observational
- Volunteers
- 32 people
- Sponsor
- Federico II University